Detalhe da pesquisa
1.
Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin-17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis.
Clin Pharmacol Drug Dev
; 13(5): 474-484, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231873
2.
Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis.
J Clin Pharmacol
; 63(1): 119-125, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35996877
3.
Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials.
J Clin Pharmacol
; 63(8): 950-960, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055934
4.
Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis.
Rheumatol Ther
; 9(6): 1587-1603, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36178584
5.
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet.
Clin Drug Investig
; 42(8): 657-668, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35829925
6.
Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.
Clin Transl Sci
; 14(4): 1611-1619, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963686
7.
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers.
Mol Cancer Ther
; 20(6): 999-1008, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785651
8.
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
Clin Pharmacokinet
; 59(3): 311-326, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31758502
9.
Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients.
Clin Pharmacol Ther
; 107(2): 378-387, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31355921
10.
Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
Clin Pharmacokinet
; 59(5): 575-589, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31667790
11.
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.
Inflamm Bowel Dis
; 26(10): 1562-1571, 2020 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32105310
12.
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Cancer Med
; 9(14): 4991-5007, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32436621
13.
Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
Clin Pharmacokinet
; 58(3): 375-387, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30123942
14.
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
Clin Pharmacokinet
; 58(10): 1309-1321, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31054118
15.
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies.
Hemasphere
; 7(12): e983, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38026788
16.
Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program.
Clin Pharmacol Ther
; 110(5): 1172-1175, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991429